trending Market Intelligence /marketintelligence/en/news-insights/trending/RmPygeUTttLx82wt7p2wvg2 content esgSubNav
In This List

GW Pharmaceuticals prices offering of ADSs


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

GW Pharmaceuticals prices offering of ADSs

GW Pharmaceuticals plc priced an underwritten public offering on the Nasdaq Global Market of 2,400,000 American depositary shares at $115 apiece.

The ADSs represent 28,800,000 ordinary shares of GW.

The U.K.-based company expects gross proceeds of about $276 million from the offering.

GW Pharmaceuticals granted underwriters a 30-day option to buy up to an additional 360,000 ADSs at the offering price.

The offering is expected to close Dec. 11.

Goldman Sachs & Co. LLC, Morgan Stanley, Bank of America Merrill Lynch and Cowen are acting as joint book-running managers for the offering.